Vol 16: Poly ADP-ribose polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer.Report as inadecuate



 Vol 16: Poly ADP-ribose polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer.


Vol 16: Poly ADP-ribose polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 16: Poly ADP-ribose polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer.
This article is from Asian Journal of Andrology, volume 16.AbstractRecent phase I studies have reported single-agent activities of poly ADP-ribose polymerase PARP inhibitor in sporadic and in BRCA-mutant prostate cancers. Two of the most common genetic alterations in prostate cancer, ETS gene rearrangement and loss of PTEN, have been linked to increased sensitivity to PARP inhibitor in preclinical models. Emerging evidence also suggests that PARP1 plays an important role in mediating the transcriptional activities of androgen receptor AR and ETS gene rearrangement. In this article, the preclinical work and early-phase clinical trials in developing PARP inhibitor-based therapy as a new treatment paradigm for metastatic prostate cancer are reviewed.



Author: Zhang, Jingsong

Source: https://archive.org/







Related documents